Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Inhibikase Therapeutics Inc stock
Learn how to easily invest in Inhibikase Therapeutics Inc stock.
Inhibikase Therapeutics Inc is a biotechnology business based in the US. Inhibikase Therapeutics Inc shares (IKT) are listed on the NASDAQ and all prices are listed in US Dollars. Inhibikase Therapeutics Inc employs 6 staff and has a trailing 12-month revenue of around $61,818.
How to buy Inhibikase Therapeutics Inc stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – IKT. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Inhibikase Therapeutics Inc stock price (NASDAQ: IKT)Use our graph to track the performance of IKT stocks over time.
Inhibikase Therapeutics Inc shares at a glance
|Latest market close||$0.66|
|52-week range||$0.44 - $1.52|
|50-day moving average||$0.58|
|200-day moving average||$0.81|
|Wall St. target price||$6.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.76|
Buy Inhibikase Therapeutics Inc stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Inhibikase Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Inhibikase Therapeutics Inc price performance over time
|1 week (2023-01-20)||-3.24%|
|1 month (2022-12-24)||N/A|
|3 months (2022-10-26)||-13.99%|
|6 months (2022-07-27)||-17.74%|
|1 year (2022-01-28)||-47.36%|
|2 years (2021-01-28)||-90.92%|
|3 years (2020-01-24)||N/A|
|5 years (2018-01-24)||N/A|
Inhibikase Therapeutics Inc financials
|Gross profit TTM||$-8,258,499|
|Return on assets TTM||-31.62%|
|Return on equity TTM||-55.1%|
|Market capitalisation||$25.2 million|
TTM: trailing 12 months
Inhibikase Therapeutics Inc share dividends
We're not expecting Inhibikase Therapeutics Inc to pay a dividend over the next 12 months.
Inhibikase Therapeutics Inc share price volatility
Over the last 12 months, Inhibikase Therapeutics Inc's shares have ranged in value from as little as $0.44 up to $1.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inhibikase Therapeutics Inc's is 0.6647. This would suggest that Inhibikase Therapeutics Inc's shares are less volatile than average (for this exchange).
To put Inhibikase Therapeutics Inc's beta into context you can compare it against those of similar companies.
Inhibikase Therapeutics Inc overview
Inhibikase Therapeutics, Inc. , a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Frequently asked questionsWhat percentage of Inhibikase Therapeutics Inc is owned by insiders or institutions?
Currently 21.32% of Inhibikase Therapeutics Inc shares are held by insiders and 18.256% by institutions. How many people work for Inhibikase Therapeutics Inc?
Latest data suggests 6 work at Inhibikase Therapeutics Inc. When does the fiscal year end for Inhibikase Therapeutics Inc?
Inhibikase Therapeutics Inc's fiscal year ends in December. Where is Inhibikase Therapeutics Inc based?
Inhibikase Therapeutics Inc's address is: 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 What is Inhibikase Therapeutics Inc's ISIN number?
Inhibikase Therapeutics Inc's international securities identification number is: US45719W1062
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert